A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT03871855
Phase
PHASE1
Status
Terminated

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR-1702 — DRUG
    Administered IV
  • Camrelizumab — DRUG
    Administered IV

Study Details

The purpose of this study is to evaluate the safety of SHR-1702 monotherapy or in combination with Camrelizumab among advanced solid tumor subjects.

Key Dates

Start date
Apr 28, 2019
Status verified
Jun 2023
Primary completion
Jun 21, 2021
Completion
Jun 21, 2021

Study Design

Enrollment
8 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A:SHR-1702 Dose Escalation
    SHR-1702 given intravenously (IV).
  • Experimental: B:SHR-1702 Dose Expansion
    SHR-1702 given intravenously (IV).
  • Experimental: C:SHR-1702 and Camrelizumab Dose Escalation
    SHR-1702 and Camrelizumab given intravenously (IV).
  • Experimental: D:SHR-1702 and Camrelizumab Dose Expansion
    SHR-1702 and Camrelizumab given intravenously (IV).

Primary Outcome Measure

Number of Participants with DLTs [ Time Frame: Approximately 28 Days ]

Related Studies